Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Bliss Biopharma of Hangzhou Licenses Cancer ADC from Morphotek

publication date: Apr 9, 2018

Morphotek, a US subsidiary of Japan's Eisai, granted Bliss Biopharmaceutical (Hangzhou) exclusive rights to use its eribulin-linker payload to develop a therapeutic antibody drug conjugate against an undisclosed oncology target for the China market. The eribulin-linker payload consists of a cytotoxic agent, eribulin, modified by a chemical linker to facilitate conjugation. The announcement did not disclose specific financial details, but the agreement is comprised of an upfront payment, milestones and sales royalties. BlissBio has an exclusive option to extend the product to the global market and to develop ADCs for two other oncology targets. More details....

Share this with colleagues:

Stock Symbol: (TYO: 4523)

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.